Acute respiratory distress syndrome (ARDS) is triggered by an initial injury to the alveolar-capillary membrane, leading to inflammation. Neutrophils play a key role by releasing proteases and reactive oxygen species, amplifying epithelial and endothelial damage. The immune system further contributes through cytokine storm, enhancing inflammation and vascular permeability. This leads to pulmonary edema, impaired gas exchange, and decreased surfactant production, ultimately causing hypoxemia and stiff lungs. The interplay between inflammation and immune response exacerbates lung injury and fibrosis.

Neutrophils play a pivotal role in acute inflammation as the first responders to infectious agents or tissue injury. They migrate to sites of inflammation via chemotaxis and perform phagocytosis of pathogens. Neutrophils release enzymes and reactive oxygen species that digest proteins and kill microbes. They also release extracellular traps to immobilize and kill pathogens. Despite their crucial role in defense, excessive activation can lead to collateral tissue damage and amplify inflammatory responses, highlighting a double-edged sword in immune defense.

Edema is the result of increased fluid accumulation in the interstitial spaces, arising from various mechanisms including elevated hydrostatic pressure, decreased oncotic pressure, increased capillary permeability, and lymphatic obstruction. Clinical implications of edema include impaired organ function, risk of infection, and tissue ischemia. Conditions such as heart failure might increase hydrostatic pressure, leading to pulmonary edema, while nephrotic syndrome can reduce oncotic pressure due to protein loss, exacerbating edema. Improved management involves targeting these underlying mechanisms to alleviate edema.

Atherosclerosis is initiated by endothelial injury, which leads to increased permeability and leukocyte adhesion. Low-density lipoprotein (LDL) cholesterol penetrates the endothelial layer and becomes oxidized. This triggers an inflammatory response, where macrophages engulf oxidized LDL to become foam cells, forming fatty streaks. Smooth muscle cells migrate and proliferate, contributing to plaque formation. Complications arise when plaques become unstable, leading to rupture and thrombosis, which can cause myocardial infarction, stroke, or peripheral arterial disease. The narrowing of arteries also leads to reduced blood flow and ischemia.

Transplant rejection is classified into hyperacute, acute, and chronic types, each involving distinct immunological mechanisms. Hyperacute rejection is mediated by pre-existing antibodies against donor antigens causing immediate graft damage. Acute rejection involves T-cell mediated responses and antibody-mediated rejection occurring days to months post-transplant, targeting donor antigens. Chronic rejection results from prolonged immune-mediated vascular injury and fibrosis, leading to graft dysfunction over years. Immunosuppressive therapies aim to minimize these immune responses to preserve graft function.

Deep vein thrombosis (DVT) occurs when thrombi form in deep veins, usually in the legs. Contributing factors include venous stasis, endothelial injury, and hypercoagulability (Virchow's triad). If parts of the thrombus dislodge, they can travel to the lungs, causing a pulmonary embolism (PE), characterized by occlusion of pulmonary arteries. PE can lead to hypoxia, right ventricular strain, reduced cardiac output, and in severe cases, sudden death. It presents clinically with dyspnea, chest pain, and hemoptysis. Prevention and treatment focus on anticoagulation and managing risk factors.

Chemical mediators like histamine, prostaglandins, cytokines, and complement proteins are crucial in orchestrating the inflammatory response. They regulate vascular changes, attract immune cells to the site of injury through chemotaxis, and modulate pain and fever. Histamine increases vascular permeability and dilation, leading to edema. Prostaglandins contribute to pain and fever, while cytokines such as TNF-alpha and IL-1 promote leukocyte recruitment and activate endothelial cells. Complement proteins aid in opsonization and cell lysis. Together, these mediators ensure a coordinated and effective defense against pathogens or injury.

During ischemia-reperfusion injury, reperfusion leads to the restoration of oxygen supply, which paradoxically results in the generation of reactive oxygen species (ROS) such as superoxide and hydroxyl radicals. These free radicals cause lipid peroxidation of cellular membranes, protein denaturation, and DNA strand breaks, leading to cellular and tissue damage. This oxidative stress disrupts cellular homeostasis and can result in cell death. Antioxidant defenses are often overwhelmed under these conditions, exacerbating the damage.

Biochemical methods of apoptosis involve initiating intrinsic and extrinsic pathways. The intrinsic pathway is regulated by mitochondria and involves the release of cytochrome c, which subsequently leads to caspase activation. The extrinsic pathway is initiated by death receptors on the cell surface leading to caspase cascade activation. Caspases, a family of cysteine proteases, are central to the execution phase of apoptosis, resulting in cell disassembly. Furthermore, the Bcl-2 family proteins regulate mitochondrial membrane permeability, playing a crucial role in controlling the release of apoptotic factors. Inhibitor of apoptosis proteins (IAPs) can bind and inhibit caspases, thus modulating apoptosis.

Systemic inflammatory response syndrome (SIRS) is characterized by an overwhelming inflammatory response, often due to infection, trauma, or other insults. It involves widespread cytokine release, endothelial activation, and immune dysregulation, leading to increased permeability and coagulopathy. The impact on organ systems includes acute respiratory distress syndrome (ARDS), acute kidney injury, and potential circulatory failure. The hyper-inflammatory state can cause multiorgan dysfunction, significantly affecting morbidity and mortality rates. Management includes addressing the underlying cause and supportive organ therapy.